Stifel Nicolaus Initiates Coverage on DexCom (NASDAQ:DXCM)

Research analysts at Stifel Nicolaus started coverage on shares of DexCom (NASDAQ:DXCM) in a research note issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $85.00 price target on the medical device company’s stock. Stifel Nicolaus’ price target would suggest a potential upside of 20.23% from the stock’s previous close.

DXCM has been the subject of several other reports. Raymond James Financial increased their price target on shares of DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Truist Financial lowered their target price on shares of DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Citigroup cut their price target on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Finally, Robert W. Baird decreased their price objective on DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $96.40.

DexCom Stock Up 1.4%

DexCom stock opened at $70.70 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market cap of $27.73 billion, a P/E ratio of 49.10, a P/E/G ratio of 1.46 and a beta of 1.47. The business has a fifty day moving average of $72.76 and a two-hundred day moving average of $77.65. DexCom has a twelve month low of $57.52 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, analysts forecast that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, Director Kyle Malady sold 667 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock valued at $564,733 over the last three months. Company insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DXCM. Horizon Investments LLC boosted its holdings in DexCom by 2.2% in the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock valued at $383,000 after purchasing an additional 123 shares during the last quarter. Wedbush Securities Inc. lifted its holdings in shares of DexCom by 1.2% in the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock valued at $899,000 after buying an additional 157 shares during the period. GAMMA Investing LLC boosted its stake in shares of DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the last quarter. Inspire Investing LLC boosted its stake in shares of DexCom by 6.1% in the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after buying an additional 180 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. grew its holdings in DexCom by 3.2% during the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock worth $407,000 after acquiring an additional 182 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.